SCYNEXIS

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell SCYNEXIS and other ETFs, options, and stocks.

About SCYX

SCYNEXIS, Inc. is a biotechnology company engaged in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. 

CEO
Marco Taglietti
CEOMarco Taglietti
Employees
56
Employees56
Headquarters
Jersey City, New Jersey
HeadquartersJersey City, New Jersey
Founded
1999
Founded1999
Employees
56
Employees56

SCYX Key Statistics

Market cap
62.06M
Market cap62.06M
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
187.27K
Average volume187.27K
High today
$1.91
High today$1.91
Low today
$1.80
Low today$1.80
Open price
$1.85
Open price$1.85
Volume
55.67K
Volume55.67K
52 Week high
$7.58
52 Week high$7.58
52 Week low
$1.70
52 Week low$1.70

SCYX Earnings

-$1.05
-$0.70
-$0.35
$0.00
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Q4 FY22
Estimated
per share
Estimated per share
Actual
Expected Mar 28, Pre-Market
ActualExpected Mar 28, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.